Title
Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction.
Document Type
Article
Publication Date
6-2014
JAX Source
Aging Cell 2014 Jun; 13(3):468-77.
Volume
13
Issue
3
First Page
468
Last Page
477
ISSN
1474-9726
PMID
24341993
Abstract
Rapamycin, an inhibitor of mTOR kinase, increased median lifespan of genetically heterogeneous mice by 23% (males) to 26% (females) when tested at a dose threefold higher than that used in our previous studies; maximal longevity was also increased in both sexes. Rapamycin increased lifespan more in females than in males at each dose evaluated, perhaps reflecting sexual dimorphism in blood levels of this drug. Some of the endocrine and metabolic changes seen in diet-restricted mice are not seen in mice exposed to rapamycin, and the pattern of expression of hepatic genes involved in xenobiotic metabolism is also quite distinct in rapamycin-treated and diet-restricted mice, suggesting that these two interventions for extending mouse lifespan differ in many respects. Aging Cell 2014 Jun; 13(3):468-77.
Recommended Citation
Miller R,
Harrison DE,
Astle CM,
Fernandez E,
Flurkey K,
Han M,
Javors M,
Li X,
Nadon N,
Nelson J,
Pletcher S,
Salmon A,
Sharp Z,
Van Roekel S,
Winkleman L,
Strong R.
Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 2014 Jun; 13(3):468-77.